CN Patent

CN102264719A — 结晶形式的有机化合物

Assigned to Sandoz AG · Expires 2011-11-30 · 14y expired

What this patent protects

本发明涉及一种结晶形式的2-[6-[3(R)-氨基哌啶-1-基]-3-甲基-2，4-二氧代-1，2，3，4-四氢嘧啶-1-基甲基]苄腈、一种制备所述结晶形式的方法及其在制造药物组合物中的用途。

USPTO Abstract

本发明涉及一种结晶形式的2-[6-[3(R)-氨基哌啶-1-基]-3-甲基-2，4-二氧代-1，2，3，4-四氢嘧啶-1-基甲基]苄腈、一种制备所述结晶形式的方法及其在制造药物组合物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number: CN102264719A
Jurisdiction: CN
Classification: —
Expires: 2011-11-30
Drug substance claim: No
Drug product claim: No
Assignee: Sandoz AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.